Alex Herrera

65PUBLICATIONS
305CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Clinical pharmacology and therapeuticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (65)

|Jun 09, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

|Mar 27, 2026
Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Ayo Samuel Falade, Robert Redd, Sanjal H Desai

|Mar 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma.

Geoffrey Shouse, Matthew Matasar, Lu Chen

|Mar 03, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.

Jennifer L Crombie, Sairah Ahmed, Matthew J Frigault

|Feb 16, 2026
Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.

Christina Poh, Jasmine Zain, James Godfrey

|Jan 09, 2026
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Sharon M Castellino, Hongli Li, Alex F Herrera

Pageof 11

Frequent Collaborators

12 joint publications

Mehdi Hamadani

10 joint publications

Lihua Elizabeth Budde

9 joint publications

Mazyar Shadman

8 joint publications

Geoffrey Shouse